116 related articles for article (PubMed ID: 23856932)
1. A STATement on vemurafenib-resistant melanoma.
Hartsough EJ; Aplin AE
J Invest Dermatol; 2013 Aug; 133(8):1928-9. PubMed ID: 23856932
[TBL] [Abstract][Full Text] [Related]
2. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
Liu F; Cao J; Wu J; Sullivan K; Shen J; Ryu B; Xu Z; Wei W; Cui R
J Invest Dermatol; 2013 Aug; 133(8):2041-9. PubMed ID: 23344460
[TBL] [Abstract][Full Text] [Related]
3. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
5. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
12. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
13. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
[TBL] [Abstract][Full Text] [Related]
14. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
Sharma A; Shah SR; Illum H; Dowell J
Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
[TBL] [Abstract][Full Text] [Related]
16. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to RAF inhibitors in melanoma.
Aplin AE; Kaplan FM; Shao Y
J Invest Dermatol; 2011 Sep; 131(9):1817-20. PubMed ID: 21593776
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
20. MITF Modulates Therapeutic Resistance through EGFR Signaling.
Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
